3.9676

3.38% 0.1176

Sagimet Biosciences Inc (SGMT)

Overview News Price History Discussions Forecast

Sagimet Biosciences Inc stock is traded at $3.9676, with a volume of 66,230. It is up +3.38% in the last 24 hours and down -1.12% over the past month. Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Previous Close:

$3.85

Open:

$3.98

24h Volume:

66,230

Relative Volume:

0.07

Market Cap:

$123.95M

Revenue:

Net Income/Loss:

$-29.25M

P/E Ratio:

-3.3454

EPS:

-1.186

Net Cash Flow:

$-22.80M

1W Performance:

+13.39%

1M Performance:

-1.12%

6M Performance:

+26.75%

1Y Performance:

-12.72%

1-Day Range:

$3.9041

$4.0303

1-Week Range:

$3.50

$4.06

52-Week Range:

$2.39

$7.38

Sagimet Biosciences Inc Stock (SGMT) Company Profile

Name

Sagimet Biosciences Inc

Sector

Healthcare (1167)

Industry

Biotechnology (670)

Phone

(650) 561-8600

Address

155 BOVET RD., SUITE 303, SAN MATEO

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SGMT's Discussions on Twitter

Compare SGMT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SGMT Sagimet Biosciences Inc	3.95	123.95M	0	-29.25M	-22.80M	-1.186
VRTX Vertex Pharmaceuticals Inc	511.71	131.61B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	670.14	73.51B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	616.99	37.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	258.66	32.81B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	263.54	28.62B	3.81B	-644.79M	-669.77M	-6.24

Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-06-24	Initiated	Oppenheimer	Outperform
Nov-12-24	Initiated	UBS	Buy
Jun-28-24	Downgrade	Goldman	Buy → Neutral
May-02-24	Initiated	H.C. Wainwright	Buy
Mar-25-24	Initiated	Leerink Partners	Outperform
Aug-08-23	Initiated	Goldman	Buy
Aug-08-23	Initiated	JMP Securities	Mkt Outperform
Aug-08-23	Initiated	Piper Sandler	Overweight
Aug-08-23	Initiated	TD Cowen	Outperform

View All

Sagimet Biosciences Inc Stock (SGMT) Latest News

01:04 AM

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $23.00 Consensus Price Target from Analysts - Defense World

01:04 AM

Mar 17, 2025

Sagimet Biosciences (SGMT) Expected to Announce Earnings on Monday - Defense World

Mar 17, 2025

HC Wainwright Issues Positive Estimate for SGMT Earnings - Defense World

Mar 17, 2025

Mar 13, 2025

Sagimet Biosciences: Promising Future with Phase 3 MASH Trials and Strong Financial Position - TipRanks

Mar 13, 2025

HC Wainwright Reiterates Buy Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World

Mar 13, 2025

Sagimet Biosciences Faces AI Integration Challenges: Security, Compliance, and Cost Risks Loom - TipRanks

Mar 13, 2025

Sagimet Biosciences Advances MASH Treatment with New Trials - TipRanks

Mar 13, 2025

Mar 12, 2025

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewswire

Mar 12, 2025

Sagimet's FDA Breakthrough Drug Enters Phase 3 Trials with $158M War Chest - StockTitan

Mar 12, 2025

Promising Developments in Sagimet Biosciences: IND Clearance for TVB-3567 and Ongoing Success of Denifanstat - TipRanks

Mar 12, 2025

Promising Pipeline and Positive Trial Data Support Buy Rating for Sagimet Biosciences - TipRanks

Mar 12, 2025

Mar 11, 2025

Sagimet Biosciences’ Strategic Expansion into Acne Treatment with Promising FASN Inhibitor TVB-3567 - TipRanks

Mar 11, 2025

Sagimet Reports Acne Drug Candidate Cleared for Clinical Trials -March 11, 2025 at 10:46 am EDT - Marketscreener.com

Mar 11, 2025

Sagimet Biosciences receives FDA nod to begin testing its therapy for acne -March 11, 2025 at 09:38 am EDT - Marketscreener.com

Mar 11, 2025

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne - SEC.gov

Mar 11, 2025

Sagimet Biosciences announces clearance of IND for FASN inhibitor TVB-3567 - TipRanks

Mar 11, 2025

Sagimet Biosciences Announces Clearance of IND for FASN - GlobeNewswire

Mar 11, 2025

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for ... - The Bakersfield Californian

Mar 11, 2025

FDA Clears Groundbreaking Acne Drug: Sagimet's New FASN Inhibitor Targets 50M Patient Market - StockTitan

Mar 11, 2025

Mar 07, 2025

Sagimet Biosciences’ Denifanstat Should Be Worth More Today (NASDAQ:SGMT) - Seeking Alpha

Mar 07, 2025

Feb 25, 2025

Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In? - Insider Monkey

Feb 25, 2025

Feb 24, 2025

10 Best Get Rich Quick Stocks To Invest In - Insider Monkey

Feb 24, 2025

Feb 23, 2025

Brokerages Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $23.00 - Defense World

Feb 23, 2025

Feb 22, 2025

10 Hot Penny Stocks to Buy Now - Insider Monkey

Feb 22, 2025

Unveiling Hidden Gems: The Hot Penny Stock You Might Be Missing - Reporteros del Sur -

Feb 22, 2025